Trial Profile
Follow-up to Study Protocol B2801001, A Phase I/II, Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 in Patients With Chronic Hepatitis C [CHC] Infection
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Oct 2018
Price :
$35
*
At a glance
- Drugs TT 034 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; First in man
- Sponsors Tacere Therapeutics
- 24 Sep 2018 Status changed from active, no longer recruiting to discontinued.
- 28 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Dec 2014 New trial record